1.
J Cutan Med Surg
; 28(1): 69-71, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37942569
2.
Ann Pharmacother
; 58(3): 333-337, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37341171
RESUMO
Treatment options for moderate-to-severe psoriasis depend on drug efficacy and safety, patient preferences, comorbidities, and cost-no drug dominates across all dimensions. Interleukin (IL)-17 inhibitors may be preferred for fast-acting treatment, while the 3-month schedule of risankizumab, ustekinumab, or tildrakizumab may be attractive for patients who prioritize fewer injections. Phototherapy is suitable for patients who wish to avoid systemic agents or when cost is a concern. For patients with poor adherence, infliximab or tildrakizumab may be well suited as they require in-office administration. Dermatologists can educate patients on available therapies to find a regimen best suited to their needs.